Scil Technology Files Patent on Coating Technology for Implants

MARTINSRIED, Germany

, May 05, 2004 - 

Scil Technology, a biopharmaceutical company focused on the development of dental tissue regeneration products, today announced it has extended its IP portfolio by a further patent application.

The technology claimed in this application allows coating of medical implants like screws, nails, stents etc. with active pharmaceutical compounds, especially recombinant proteins. The process, which retains the native structure and activity of a protein when directly coated onto the surface of a metal implant is easily transferable to large scale aseptic manufacturing.

The Company plans to use this technology in the first instance for the commercial, cost effective manufacturing of regenerative, growth factor activated dental implants. These will be developed for patients who have a risk for lower dental implant success rates because of their poor jaw bone quality caused by insufficient oral hygiene, heavy smoking, osteoporosis or insufficiently treated diabetes associated with high blood sugar level.

In addition to the activated dental implants the technology could also be applied to orthopaedic implants for various applications.

Dr Irina Staatz-Granzer, Managing Director of Scil Technology, commented:
“Scil Technology has pioneered this unique coating technology, which will allow us to develop regenerative, activated implants that actually facilitate the osseointegration of the respective implants.”

About Scil Technology GmbH

Scil Technology is a private biopharmaceutical development company focused on dental and orthopaedic tissue regeneration with a particular emphasis on bone and cartilage repair. The Company’s lead therapeutic candidates are based on recombinant, highly specific human growth factors. These are combined with biodegradable biomaterials to generate local application forms. Scil Technology’s pipeline for dentistry includes products that are targeted at periodontal disease, dental implantology and maxillofacial surgery. Orthopaedic products are developed for spinal fusion, traumatic lesions of  bone and cartilage tissue  and osteoarthritis. Scil Technology has emerged from the Scil Group and is located in the biotechnology cluster in Martinsried, Germany.

For more information please visit: http://www.scil.com

Contacts

Media relations:

Sue Charles, MA, MBA, CEO
Northbank Communications
t : +44 (0) 20 7886 8152
e: s.charles@northbankcommunications.com

Douglas Pretsell, Ph.D., Senior Account Manager
Northbank Communications
t : +44 (0) 20 7886 8158
e:  d.pretsell@northbankcommunications.com

At Scil Technology:

Dr Irina Staatz-Granzer, Managing Director
Scil Technology GmbH
t: +49 (0)89 85651824
e: irina.staatz@scil.com